These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15600382)

  • 81. Metabolic effects of treatment with atypical antipsychotics.
    Kane JM; Barrett EJ; Casey DE; Correll CU; Gelenberg AJ; Klein S; Newcomer JW
    J Clin Psychiatry; 2004 Nov; 65(11):1447-55. PubMed ID: 15554755
    [No Abstract]   [Full Text] [Related]  

  • 82. Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis.
    Kanagasundaram P; Lee J; Prasad F; Costa-Dookhan KA; Hamel L; Gordon M; Remington G; Hahn MK; Agarwal SM
    Front Psychiatry; 2021; 12():642403. PubMed ID: 33815174
    [No Abstract]   [Full Text] [Related]  

  • 83. Metabolic issues and cardiovascular disease in patients with psychiatric disorders.
    Casey DE
    Am J Med; 2005 Apr; 118 Suppl 2():15S-22S. PubMed ID: 15903291
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Pancreatitis associated with metformin used for management of clozapine-related weight gain.
    McFadden M; Gordon A; Leong G; Ward D; Scott JG
    Aust N Z J Psychiatry; 2016 Jul; 50(7):701-2. PubMed ID: 26883571
    [No Abstract]   [Full Text] [Related]  

  • 85. Drug-induced metabolic syndrome.
    Wofford MR; King DS; Harrell TK
    J Clin Hypertens (Greenwich); 2006 Feb; 8(2):114-9. PubMed ID: 16470080
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.
    Yamamoto K; Fukuda M; Nogawa A; Takahashi E; Miyaoka H
    J Clin Psychiatry; 2007 May; 68(5):802. PubMed ID: 17503998
    [No Abstract]   [Full Text] [Related]  

  • 87. Confounding by indication and the risk of hyperlipidemia in observational studies of antipsychotics.
    Rico-Villademoros F; Calandre EP
    Am J Psychiatry; 2007 Mar; 164(3):525-6; author reply 526. PubMed ID: 17329481
    [No Abstract]   [Full Text] [Related]  

  • 88. Metabolic risks and effects of atypical antipsychotic treatment.
    Haupt DW; Kane JM
    J Clin Psychiatry; 2007 Oct; 68(10):e24. PubMed ID: 17960957
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nutritional approach to metabolic changes arising out of schizophrenia therapy: case report.
    Ozenoglu A; Ugurlu S; Balci H; Eker E
    Intern Med; 2007; 46(15):1213-8. PubMed ID: 17675772
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Diabetes mellitus associated with atypical antipsychotic medications: case report and review of the literature].
    Reis JS; Alvarenga T; Rosário PW; Menezes PA; Rocha Rdos S; Purisch S
    Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):488-93. PubMed ID: 17546250
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Psychosis and delirium following metabolife use.
    Verduin ML; Labbate LA
    Psychopharmacol Bull; 2002; 36(3):42-5. PubMed ID: 12473963
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Weight gain profiles of new anti-psychotics: public health consequences.
    Tardieu S; Micallef J; Gentile S; Blin O
    Obes Rev; 2003 Aug; 4(3):129-38. PubMed ID: 12916814
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes.
    Lean ME; Pajonk FG
    Diabetes Care; 2003 May; 26(5):1597-605. PubMed ID: 12716824
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cardiovascular effects of psychotic illnesses and antipsychotic therapy.
    Howell S; Yarovova E; Khwanda A; Rosen SD
    Heart; 2019 Dec; 105(24):1852-1859. PubMed ID: 31439658
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Lipid effects of psychiatric medications.
    Watanabe J; Suzuki Y; Someya T
    Curr Atheroscler Rep; 2013 Jan; 15(1):292. PubMed ID: 23225174
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antipsychotic-induced weight gain.
    Goudie AJ; Cooper GD; Halford JC
    Diabetes Obes Metab; 2005 Sep; 7(5):478-87. PubMed ID: 16050940
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Meralgia paresthetica: another complication of antipsychotic-induced weight gain.
    Chlebowski S; Bashyal S; Schwartz TL
    Obes Rev; 2009 Nov; 10(6):700-2. PubMed ID: 19413704
    [No Abstract]   [Full Text] [Related]  

  • 98. Olanzapine: a new risk factor for pulmonary embolus?
    Kannan R; Molina DK
    Am J Forensic Med Pathol; 2008 Dec; 29(4):368-70. PubMed ID: 19259029
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Treating the mind and body in schizophrenia: risks and prevention.
    Meyer JM
    CNS Spectr; 2004 Oct; 9(10 Suppl 11):25-33. PubMed ID: 15475874
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study.
    Yoshida K; Marshe VS; Elsheikh SSM; Maciukiewicz M; Tiwari AK; Brandl EJ; Lieberman JA; Meltzer HY; Kennedy JL; Müller DJ
    Pharmacogenomics J; 2023 Sep; 23(5):119-126. PubMed ID: 37106021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.